This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.
NVOPositive Net Change AGENNegative Net Change CPRXNegative Net Change INOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
by Sundeep Ganoria
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
NVAXPositive Net Change SRPTPositive Net Change CYTKNegative Net Change ANIPNegative Net Change RVMDPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
by Zacks Equity Research
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
SNYPositive Net Change GILDPositive Net Change CSTLPositive Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
by Zacks Equity Research
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
ALKSNegative Net Change PCRXNegative Net Change CPRXNegative Net Change INOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
by Zacks Equity Research
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change ALKSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
by Zacks Equity Research
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
MRKPositive Net Change VRTXPositive Net Change MRNAPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals
Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
GRDN heads into Q1 earnings with revenues seen at $329.7M, as growth trends, vaccine volumes and IRA pricing impacts take center stage.
UTHRPositive Net Change ANIPNegative Net Change ACADNegative Net Change GRDNNegative Net Change
biotechs
Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit Gains
by Zacks Equity Research
AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.
AZNPositive Net Change NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
AGENNegative Net Change INOPositive Net Change AKBAPositive Net Change QTTBPositive Net Change
biotechs